Cellectis S.A. (CMVLF)
CMVLF Stock Price Chart
Explore Cellectis S.A. interactive price chart. Choose custom timeframes to analyze CMVLF price movements and trends.
CMVLF Company Profile
Discover essential business fundamentals and corporate details for Cellectis S.A. (CMVLF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jul 2014
Employees
216.00
Website
https://www.cellectis.comCEO
Andre Choulika
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CMVLF Financial Timeline
Browse a chronological timeline of Cellectis S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Mar 2026
Upcoming earnings on 3 Nov 2025
Earnings released on 4 Aug 2025
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.21%, while revenue for the quarter reached $18.53M , beating expectations by +125.38%.
Earnings released on 12 May 2025
EPS came in at -$0.18 falling short of the estimated -$0.15 by -18.12%, while revenue for the quarter reached $10.66M , missing expectations by -16.18%.
Earnings released on 13 Mar 2025
EPS came in at $0.06 surpassing the estimated -$0.18 by +132.89%, while revenue for the quarter reached $12.72M , beating expectations by +38.68%.
Earnings released on 4 Nov 2024
EPS came in at -$0.23 surpassing the estimated -$0.24 by +3.68%, while revenue for the quarter reached $16.42M , missing expectations by -19.57%.
Earnings released on 6 Aug 2024
EPS came in at -$0.28 falling short of the estimated -$0.28 by -0.76%, while revenue for the quarter reached $8.02M , beating expectations by +101.89%.
Earnings released on 28 May 2024
EPS came in at $0.05 surpassing the estimated -$0.20 by +127.51%, while revenue for the quarter reached $4.50M , beating expectations by +146.19%.
Earnings released on 13 Mar 2024
EPS came in at -$0.61 falling short of the estimated -$0.29 by -111.61%, while revenue for the quarter reached $290.45K , missing expectations by -83.86%.
Earnings released on 30 Sept 2023
EPS came in at -$0.31 surpassing the estimated -$0.41 by +23.76%, while revenue for the quarter reached $155.00K , missing expectations by -95.61%.
Earnings released on 30 Jun 2023
EPS came in at -$0.19 surpassing the estimated -$0.44 by +56.11%, while revenue for the quarter reached $178.00K , missing expectations by -96.01%.
Earnings released on 31 Mar 2023
EPS came in at -$0.58 falling short of the estimated -$0.48 by -20.62%, while revenue for the quarter reached $139.00K , missing expectations by -97.70%.
Earnings released on 8 Mar 2023
EPS came in at -$0.58 surpassing the estimated -$0.81 by +28.40%, while revenue for the quarter reached $16.02M , missing expectations by -18.43%.
Earnings released on 3 Nov 2022
EPS came in at -$0.63 falling short of the estimated -$0.54 by -16.67%, while revenue for the quarter reached $217.00K , missing expectations by -98.69%.
Earnings released on 4 Aug 2022
EPS came in at -$0.42 surpassing the estimated -$0.68 by +38.24%, while revenue for the quarter reached $1.35M , missing expectations by -94.27%.
Earnings released on 12 May 2022
EPS came in at -$0.62 surpassing the estimated -$0.64 by +3.13%, while revenue for the quarter reached $1.70M , missing expectations by -90.99%.
Earnings released on 3 Mar 2022
EPS came in at -$0.48 surpassing the estimated -$1.10 by +56.36%, while revenue for the quarter reached $13.65M , beating expectations by +38.49%.
Earnings released on 4 Nov 2021
EPS came in at -$0.71 falling short of the estimated -$0.55 by -29.09%, while revenue for the quarter reached $8.31M .
Earnings released on 5 Aug 2021
EPS came in at -$0.73 falling short of the estimated -$0.60 by -21.67%, while revenue for the quarter reached $11.18M .
Earnings released on 6 May 2021
EPS came in at -$0.28 , while revenue for the quarter reached $25.60M .
Earnings released on 4 Mar 2021
EPS came in at -$0.95 , while revenue for the quarter reached $13.65M .
Earnings released on 5 Nov 2020
EPS came in at -$0.71 , while revenue for the quarter reached $6.18M .
CMVLF Stock Performance
Access detailed CMVLF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.